Prostate Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The systemic treatment of prostate cancer has evolved to feature interference with androgen signaling that fuels malignant cancer cell growth and progression, the possible early use of taxane chemotherapy, the availability of bone-targeted agents that reduce skeletal complications of metastatic disease and its treatment, and the emergence of various immunotherapies. New drug development has seen nine new agents approved for prostate cancer over a little more than a decade. Molecular insights into prostatic carcinogenesis and life-threatening prostate cancer progression are illuminating new opportunities for treatment development and refinement, defining mechanisms of treatment sensitivity and resistance. Hopefully, prostate cancer deaths, which have been on the decline for several years, can eventually be eliminated with new treatments and new treatment strategies.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley-Blackwell
Pages273-286
Number of pages14
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015

Keywords

  • Androgen deprivation
  • Androgen receptor
  • Anti-androgen
  • Bisphosphonate
  • Prostate cancer
  • Taxane

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Prostate Cancer'. Together they form a unique fingerprint.

Cite this